<DOC>
	<DOCNO>NCT02262637</DOCNO>
	<brief_summary>Study evaluate efficacy tolerability Micardis速/MicardisPlus速 usual daily-practice prescribing-conditions emphasis effect endorgan damage clientele cardiologist , nephrologists , diabetologists</brief_summary>
	<brief_title>Micardis速 / MicardisPlus速 Program Therapy Optimization With Telmisartan Cardiovascular Diseases ( PROTEKT )</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Telmisartan , hydrochlorothiazide drug combination</mesh_term>
	<criteria>Age &gt; = 18 year Age &lt; 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>